Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he ...
Pharmaceutical Technology on MSN
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
The company is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent expiries within its portfolio.
Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. | Luke Miels had only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results